A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia

Journal of Neuroscience

Volumn 26, Issue 11, 2006, Pages 2914-2922

  Gardoni, Fabrizio ^a   Picconi, Barbara ^b   Ghiglieri, Veronica ^b   Polli, Federica ^a   Bagetta, Vincenza ^b   Bernardi, Giorgio ^b,c   Cattabeni, Flaminio ^a   Di Luca, Monica ^a   Calabresi, Paolo ^b,d  

^a UNIVERSITY OF MILAN   (Italy)

^b EUROPEAN BRAIN RESEARCH INSTITUTE   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d UNIVERSITY OF PERUGIA   (Italy)

Author keywords

6 OHDA; Dyskinesia; MAGUK; Nmda receptor; Parkinson's disease; Rat

Indexed keywords

BENSERAZIDE; LEVODOPA; MEMBRANE ASSOCIATED GUANYLATE CYCLASE KINASE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; OXIDOPAMINE; POSTSYNAPTIC DENSITY PROTEIN 95; SYNAPSE ASSOCIATED PROTEIN 102; SYNAPSE ASSOCIATED PROTEIN 97; SYNTHETIC PEPTIDE; TAT2B; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORPUS STRIATUM; DENERVATION; DYSKINESIA; MALE; MEMORY; MOTOR DYSFUNCTION; NONHUMAN; POSTSYNAPTIC MEMBRANE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; RAT; SYNAPSE; SYNAPTIC MEMBRANE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTIPARKINSON AGENTS; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CORPUS STRIATUM; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEVODOPA; MALE; MEMBRANE PROTEINS; MOTOR ACTIVITY; NEUROPEPTIDES; OXIDOPAMINE; PARKINSONIAN DISORDERS; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STRUCTURE, TERTIARY; PROTEIN TRANSPORT; PROTEIN-TYROSINE KINASES; PSYCHOMOTOR PERFORMANCE; RATS; RATS, WISTAR; RECEPTORS, N-METHYL-D-ASPARTATE; RECOMBINANT FUSION PROTEINS; SUBCELLULAR FRACTIONS; SYNAPSES;

EID: 33644995350     PISSN: 02706474     EISSN: 02706474     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.5326-05.2006     Document Type: Article

References (33)

1. Aarts M, Liu Y, Liu L, Besshoh S, Arundine M, Gurd JW, Wang YT, Salter MW, Tymianski M (2002) Treatment of ischemic brain damage by perturbing NMDA receptor-PSD-95 protein interactions. Science 298:846-850.
2. Cenci MA, Lee CS, Björklund A (1998) L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci 10:2694-2706.
3. 1 receptor-dependent trafficking of striatal NMDA glutamate receptors to the postsynaptic membrane. J Neurosci 21:5546-5558.
4. Dunah AW, Wang Y, Yasuda RP, Kameyama K, Huganir RL, Wolfe BB, Standaert DG (2000) Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-D-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson's disease. Mol Pharmacol 57:342-352.
5. Gardoni F, Caputi A, Cimino M, Pastorino L, Cattabeni F, Di Luca M (1998) Calcium/calmodulin-dependent protein kinase II is associated with NR2A/B subunits of NMDA receptor in postsynaptic densities. J Neurochem 71:1733-1741.
6. 2+/calmodulin-dependent protein kinase II and postsynaptic density 95 for binding to the NR2A subunit of the NMDA receptor. J Neurosci 21:1501-1509.
7. Gardoni F, Mauceri D, Fiorentini C, Bellone C, Missale C, Cattabeni F, Di Luca M (2003a) CaMKII-dependent phosphorylation regulates SAP97/ NR2A interaction. J Biol Chem 278:44745- 44752.
8. Gardoni F, Pagliardini S, Setola V, Bassanini S, Cattabeni F, Battaglia G, Di Luca M (2003b) The NMDA receptor complex is altered in an animal model of human cerebral heterotopia. J Neuropathol Exp Neurol 62:662-675.
9. Hadj Tahar A, Gregoire L, Darre A, Belanger N, Meltzer L, Bedard PJ (2004) Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys. Neurobiol Dis 15:171-176.
10. Hallett PJ, Dunah AW, Ravenscroft P, Zhou S, Bezard E, Crossman AR, Brotchie JM, Standaert DG (2005) Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Neuropharmacology 48:503-516.
11. Hardingham GE, Fukunaga Y, Bading H (2002) Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci 5:405-414.
12. Kim E, Sheng M (2004) PDZ domain proteins of synapses. Nat Rev Neurosci 5:771-781.
13. Lang AP, Lozano AE (1998) Parkinson's disease. N Engl J Med 339:1044-1053.
14. Lim IA, Merrill MA, Chen Y, Hell JW (2003) Disruption of the NMDA receptor-PSD-95 interaction in hippocampal neurons with no obvious physiological short-term effect. Neuropharmacology 45:738-754.
15. Loschmann PA, De Groote C, Smith L, Wullner U, Fischer G, Kemp JA, Jenner P, Klockgether T (2004) Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease. Exp Neurol 187:86-93.
16. Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, Cenci MA (2002) Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur J Neurosci 15:120-132.
17. Menegoz M, Lau LF, Herve D, Huganir RL, Girault JA (1995) Tyrosine phosphorylation of NMDA receptor in rat striatum: effects of 6-OH-dopamine lesions. NeuroReport 7:125-128.
18. Nash JE, Fox SH, Henry B, Hill MP, Peggs D, McGuire S, Maneuf Y, Hille C, Brotchie JM, Crossman AR (2000) Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease. Exp Neurol 165:136-142.
19. Nash JE, Ravenscroft P, McGuire S, Crossman AR, Menniti FS, Brotchie JM (2004) The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease. Exp Neurol 188:471-479.
20. Nash JE, Johnston GL, Collingridge GL, Garner CC, Brotchie JM (2005) Subcellular redistribution of the synapse-associated proteins PSD-95 and SAP97 in animal models of Parkinson's disease and L-DOPA-induced dyskinesia. FASEB J 19:583-585.
21. Obeso JA, Olanow CW, Nutt JC (2000) Levodopa motor complications in Parkinson's disease. Trends Neurosci 23:S2-S7.
22. Oh JD, Vaughan CL, Chase TN (1999) Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal NMDA receptor subunits. Brain Res 821:433-442.
23. Omkumar RV, Kiely MJ, Rosenstein AJ, Min KT, Kennedy MB (1996) Identification of a phosphorylation site for calcium/calmodulin dependent protein kinase II in the NR2B subunit of the N-methyl-D-aspartate receptor. J Biol Chem 271:31670-31678.
24. Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates. Orlando, FL: Academic.
25. Picconi B, Centonze D, Hakansson K, Bernardi G, Greengard P, Fisone G, Cenci MA, Calabresi P (2003) Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci 6:501-506.
26. 2+-calmodulin-dependent protein kinase II function mediates synaptic and motor deficits in experimental parkinsonism. J Neurosci 24:5283-5291.
27. Prybylowski K, Wenthold RJ (2004) N-Methyl-D-aspartate receptors: subunit assembly and trafficking to the synapse. J Biol Chem 279:9673-9676.
28. Sans N, Prybylowski K, Petralia RS, Chang K, Wang YX, Racca C, Vicini S, Wenthold RJ (2003) NMDA receptor trafficking through an interaction between PDZ proteins and the exocyst complex. Nat Cell Biol 5:520-530.
29. Schwarting RK, Huston JP (1996) The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog Neurobiol 50:275-331.
30. Sheng M (2001) Molecular organization of the postsynaptic specialization. Proc Natl Acad Sci USA 98:7058-7061.
31. Strack S, Colbran RJ (1998) Autophosphorylation-dependent targeting of calcium/ calmodulin-dependent protein kinase II by the NR2B subunit of the N-methyl-D-aspartate receptor. J Biol Chem 273:20689-20692.
32. Tovar KR, Westbrook GL (2002) Mobile NMDA receptors at hippocampal synapses. Neuron 34:255-264.
33. Wessell RH, Ahmed SM, Menniti FS, Dunbar GL, Chase TN, Oh JD (2004) NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats. Neuropharmacology 47:184-194.